Smart Guide,peptide

The realm of cyclic peptides is vast and ever-expanding, encompassing a diverse array of molecules with significant implications in medicine, biology, and synthetic chemistry. These unique polypeptide chains, characterized by their circular structure, have transitioned from laboratory curiosities to clinically vital therapeutics. This article delves into the comprehensive landscape of all cyclic peptides ever discovered and utilized, exploring their history, properties, applications, and the latest advancements in their development.

Defining Cyclic Peptides: Structure and Characteristics

At their core, cyclic peptides are polypeptide chains which contain a circular sequence of bonds. Unlike linear peptides, where amino acids are linked in a straightforward chain, cyclic peptides form a ring. This cyclization can occur through various linkages, including the head-to-tail amide bond, side-chain-to-side-chain linkages, or head-to-side-chain connections. The specific method of cyclization, such as lactam, disulfide-bridged, or stapled scaffolds, contributes to their distinct conformational properties.

A key characteristic of many cyclic peptides is their ability to contain alternating L and D amino acids, which significantly influences their conformational stability. This structural feature often leads to a more rigid and defined three-dimensional structure compared to their linear counterparts. This conformational rigidity is crucial for their high specificity and affinity when interacting with biological targets. The molecular weight of these polypeptide chains typically ranges from about 500 to 2000 Da, with a common sequence length of 5 to 14 amino acids.

A Historical Perspective: From Discovery to Clinical Mainstays

The journey of cyclic peptides in medicine began decades ago. The first cyclic peptide hormones exploited as drugs were oxytocin and vasopressin, introduced to the clinic in the 1960s. These early successes paved the way for further research and development. The discovery of cyclolinopeptide A (from flax) is noted as a significant milestone, being identified as the first known plant cyclic peptide.

The past few decades have witnessed an exponential growth in the development and approval of cyclic peptides for therapeutic use. As of 2024, global regulatory agencies have approved a substantial number of peptide-based drugs. In the last two decades alone, approximately 18 cyclic peptides have been approved for clinical use, with a notable surge in recent years. For instance, in 2023, three out of six approved peptide drugs were cyclic: Rezafungin (for candidemia), Motixafortide (targeting CXCR4 in multiple myeloma), and an unnamed third. This trend highlights the increasing recognition of their therapeutic potential. As of early 2020, there were already over 40 cyclic peptides in clinical use, with several more in clinical trials.

Therapeutic Applications and Approved Drugs

The unique structural attributes of cyclic peptides grant them remarkable stability and bioactivity, making them powerful candidates for treating a wide range of diseases. Their ability to bind to a broader range of protein targets than traditional small molecules is a significant advantage in drug development. This has led to their successful application in various therapeutic areas, including oncology, infectious diseases, and autoimmune disorders.

The development of cyclic peptide drugs has evolved considerably. While initially many were derived from natural sources or modified natural products, newer strategies focus on *de novo* development. Peginesatide stands out as the first cyclic peptide drug developed *de novo*, marking a shift in the research and development landscape. The coming of age of cyclic peptide drugs is evident in the growing pipeline and the increasing number of approvals.

Advancements in Synthesis and Research

The synthesis of cyclic peptides has seen significant advancements, enabling researchers to create increasingly complex and diverse structures. Several general methods are employed, including head-to-tail cyclization, side-chain-to-side-chain, head-to-side-chain, and other specialized techniques. The ability to perform custom synthesis of cyclic peptides is crucial for researchers and pharmaceutical companies seeking to explore novel therapeutic candidates.

Recent breakthroughs, such as the first-ever ribosomal synthesis of cyclic peptides, are opening new avenues for their production and application. This innovative approach expands the range of ring-shaped backbones that can be synthesized using ribosomes, a fundamental biological machinery. Furthermore, the unification of fragmented public repositories into a single curated resource, such as one containing 930 cyclic peptides, is accelerating research by providing a comprehensive knowledge base.

The field continues to push boundaries, with researchers developing libraries of cyclic peptides for screening against specific disease targets. For example, a library of 8,448 cyclic peptides was synthesized and screened against thrombin, demonstrating a powerful workflow for *de novo* development. The largest synthetic cyclic peptide ever made is a testament to the ingenuity in this field, featuring a 124-atom ring.

Entities, LSIs, and Variations in the Cyclic Peptide Landscape

The study and application of cyclic peptides involve a rich ecosystem of related entities, latent semantic indexing (LSI) terms, and variations. Key entities frequently encountered include specific drugs like **Alameth